Previous 10 | Next 10 |
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors PR Newswire Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired...
Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference Canada NewsWire SAN DIEGO, Calif. and CALGARY, AB , May 10, 2022 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: O...
Oncolytics Biotech, Inc. (ONCY) Q1 2022 Earnings Conference Call May 5, 2022 17:00 ET Corporate Participants Jon Patton - Director, Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Globa...
Oncolytics Biotech press release (NASDAQ:ONCY): Q1 GAAP EPS of -$0.12 misses by $0.01. $39.5M in cash and cash equivalents expected to provide runway through key catalysts and into 2023. Top-line data from phase 2 BRACELET-1 metastatic breast cancer study expected in Q4 2022. For further de...
Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights Canada NewsWire Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational tri...
Oncolytics Biotech (NASDAQ:ONCY) is scheduled to announce Q1 earnings results on Thursday, May 5th, after market close. The consensus EPS Estimate is -$0.11 (vs. -$0.13 last year). For further details see: Oncolytics Biotech Q1 2022 Earnings Preview
Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years and will continue in the years to come. Breast cancer ...
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting PR Newswire Pelareorep treatment resulted in a favorable Risk of Recurrence ...
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting Canada NewsWire SAN DIEGO, Calif. and CALGARY, AB , May 2, 2022 /CNW/ -- Oncolytics Biotech ® Inc. (NA...
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Canada NewsWire Conference call and webcast to take place on Thursday, May 5, 2022 , at 5:00 p.m. ET SAN DIEGO and CALGAR...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Canada NewsWire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report ove...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Canada NewsWire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast ca...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...